// App-Quantinova.ai

: PULSAR open-label extension: interim results from a phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH)

Researchers

Presenter

  • David Badesch

Principal Investigators

  • Simon Gibbs

  • Mardi Gomberg-Maitland

  • Marius Hoeper

  • Vallerie Mclaughlin

  • Ioana Preston

  • Rogerio Souza

  • Aaron Waxman

  • Solaiappan Manimaran

  • Jennifer Barnes

  • Janethe De Oliveira Pena

  • Marc Humbert

  • Marius M. Hoeper

Medical Centers

  • Acceleron Pharma, Cambridge, United States of America

  • Tufts Medical Center, Boston, United States

  • University of Michigan - Ann Arbor - United States of America

  • University of Paris-Saclay, Assistance Publique Hopitaux de Paris, Le Kremlin-Bicêtre, France

  • Department of Respiratory Medicine, Hannover Medical School and German Center of Lung Research, Hannover, Germany,

  • Brigham and Womens Hospital, Boston, MA, United States

  • University of Sao Paulo, Sao Paulo, Brazil

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • University of Paris-Saclay, Hannover, Germany

Locations

  • United States

  • United Kingdom

  • Germany

  • France

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Pulmonary arterial hypertension

Biomarkers

  • N/A

Drug/Treatment

  • Sotatercept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved